Clinical Trials Logo

Filter by:
NCT ID: NCT02525744 Completed - Healthy Clinical Trials

A Study of a New LY900014 Formulation in Healthy Participants

Start date: August 2015
Phase: Phase 1
Study type: Interventional

This study evaluates a new formulation of LY900014, a drug that lowers blood sugar. It is administered by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will last for about 8 to 9 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.

NCT ID: NCT02524548 Completed - Breast Cancer Clinical Trials

SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors

Start date: May 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether weekly SMS reminders are effective in improving medication adherence of adjuvant aromatase inhibitors in women with breast cancer.

NCT ID: NCT02516345 Completed - Physical Activity Clinical Trials

Randomized Controlled Trial of an Incentive-based Physical Activity Program Targeting Both Children and Adults (FIT-FAM)

FIT-FAM
Start date: November 25, 2015
Phase: N/A
Study type: Interventional

This study aims to test whether incentives can motivate children to promote increased physical activity of a working parent while also increasing their own activity levels.

NCT ID: NCT02516072 Completed - Clinical trials for Contrast Induced Nephropathy

Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy

Start date: January 2015
Phase: N/A
Study type: Interventional

With an increasingly ageing population the incidence of peripheral arterial disease (PAD) is rising. With approximately one quarter of all PAD patients ultimately progressing to Critical Limb Ischaemia (CLI), increased demands are being placed on vascular imaging to accurately assess stenotic lesions. Early infrainguinal lesions (i.e. TASC A & B) can be treated with angioplasty+/- stenting and accurate assessment relies on the imaging gold standard of angiography. Patients with PAD often have concomitant co morbidities such as diabetes and chronic renal impairment placing them at increased risk of developing contrast induced nephropathy (CIN) when exposed to iodinated contrast media. High risk individuals with decreased eGFR <60ml/min have a risk of between 20-30% of developing CIN. They have increased morbidity and mortality risks with a greater need for dialysis and prolonged in patient hospital stays. Ideally, the investigators should be searching for ways to decrease the incidence of CIN. Animal studies and more recently pilot human trials have shown that subjecting a remote vascular bed to a brief ischaemic stress, followed by a period of reperfusion; in what has been termed remote ischemic preconditioning (RIPC), may confer a protective benefit against the development of CIN. This study aims to determine if RIPC can protect against CIN in patients undergoing elective peripheral angiography for infrainguinal disease.

NCT ID: NCT02509988 Completed - Hyperglycemia Clinical Trials

Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health

NiPPeR
Start date: July 2015
Phase: N/A
Study type: Interventional

The study aims to assess whether a nutritional drink taken before conception and continuing through pregnancy, assists in the maintenance of healthy glucose metabolism in the mother and promotes offspring health.

NCT ID: NCT02508467 Completed - Clinical trials for Hepatocellular Carcinoma (HCC)

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Start date: July 31, 2015
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of fisogatinib (formerly known as BLU- 554) administered orally in patients with FGF19 IHC+ hepatocellular carcinoma (HCC). The study consists of 3 parts, a dose-escalation part (Part 1), an expansion part (Part 2) exploring a once daily (qd) dosing schedule at the recommended Phase 2 dose (RP2D), and a Part 3 expansion of the qd dosing schedule at the RP2D in TKI naive patients.

NCT ID: NCT02507895 Completed - Stroke Clinical Trials

Effect of Brain-Computer Interfaced-Assisted Motor Imagery for Gait Retraining in Stroke Patients

Start date: October 2013
Phase: N/A
Study type: Interventional

Currently the process for stroke recovery is slow with majority of its treatments focused around physical therapy. Among the many methods employed to facilitate recovery in stroke, the use of motor imagery (MI) training may be beneficial towards stroke rehabilitation. In the current study, we propose 2 aims. Our first aim is to determine the feasibility and efficacy of a novel brain-computer interface-assisted MI train program (BCI-MI) in patients with chronic ischemic stroke. This is designed as a proof-of-concept study that only require a single-session trial. If patients successfully activate the BCI-MI system without much difficulty, our second aim is to enroll patients into a 4-week training program using the BCI-MI. Both functional magnetic resonance imaging (fMRI) and transcranial magnetic stimulation (TMS) will be done to determine the effects of the 4-week training program. Subjects may potentially see improvements in walking gait as preliminary data from previous studies have demonstrated positive results.

NCT ID: NCT02506569 Completed - Clinical trials for Safety of MR (Magnetic Resonance)-Conditional ICDs

ProMRI 3T ENHANCED Master Study

Start date: January 2015
Phase: N/A
Study type: Observational

The investigation is designed to provide supporting evidence for the clinical safety of the Biotronik's new Implantable Cardioverter Defibrillator systems when used under specific 3 Tesla MR conditions .

NCT ID: NCT02504268 Completed - Clinical trials for Rheumatoid Arthritis

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

AVERT-2
Start date: September 3, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.

NCT ID: NCT02497950 Completed - Heart Failure Clinical Trials

HeartMate 3 ELEVATEā„¢ Registry

ELEVATEā„¢
Start date: October 13, 2015
Phase:
Study type: Observational [Patient Registry]

Evaluate real-world experience of HeartMate 3 (HM3) in post-approval setting.